Press Releases
Talking COVID-19 Vaccine Cooperation with John Rim
Demand for bio-medicines in a rapidly changing global environment is increasing day by day. Amid growing global interest in the COVID-19 vaccine as a critical key to ending the pandemic, Samsung Biologics drew attention from both the media and the industry for its recent agreement for the fill-finish manufacturing of Moderna’s COVID-19 vaccine.
Recently, John Rim, CEO of Samsung Biologics, had an interview with Thomas Byrne, President and CEO of The Korea Society, a nonprofit organization that aims to promote greater awareness, mutual understanding, and cooperation between the U.S. and South Korea.
The Korea Society’s “President's Interview Series” particularly explores the economic, financial, and business relations between South Korea and the U.S. In addition to sharing the current outlook of the pharmaceutical industry, CEO John Rim discussed Samsung Biologics' capabilities to manufacture mRNA vaccines, its role in the ongoing pandemic as a leading global CDMO, and its future growth vision.
To watch the full interview, please click on the video below.
If you want to read about Samsung Biologics’ COVID-19 vaccine agreement with Moderna and our plans to add mRNA vaccine DS production capability to its facilities, please visit our Newsroom for more information.
Demand for bio-medicines in a rapidly changing global environment is increasing day by day. Amid growing global interest in the COVID-19 vaccine as a critical key to ending the pandemic, Samsung Biologics drew attention from both the media and the industry for its recent agreement for the fill-finish manufacturing of Moderna’s COVID-19 vaccine.
Recently, John Rim, CEO of Samsung Biologics, had an interview with Thomas Byrne, President and CEO of The Korea Society, a nonprofit organization that aims to promote greater awareness, mutual understanding, and cooperation between the U.S. and South Korea.
The Korea Society’s “President's Interview Series” particularly explores the economic, financial, and business relations between South Korea and the U.S. In addition to sharing the current outlook of the pharmaceutical industry, CEO John Rim discussed Samsung Biologics' capabilities to manufacture mRNA vaccines, its role in the ongoing pandemic as a leading global CDMO, and its future growth vision.
To watch the full interview, please click on the video below.
If you want to read about Samsung Biologics’ COVID-19 vaccine agreement with Moderna and our plans to add mRNA vaccine DS production capability to its facilities, please visit our Newsroom for more information.